Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer
Key Appointment to Advance Pipeline of Targeted Protein Degradation Therapeutics into the Clinic
Cambridge, Mass. (September 20, 2018) – Kymera Therapeutics LLC, a biotechnology company pioneering targeted protein degradation as a transformative new approach to creating breakthrough medicines for patients, today announced the appointment of Jared Gollob, MD, to the role of Chief Medical Officer. Formerly Vice President of Clinical Development and Global Vice President of Medical Affairs at Alnylam Pharmaceuticals, Dr. Gollob joins to build and lead Kymera’s clinical strategy and organization.
“Kymera is a company of great people built on great science. We are rapidly advancing our first drug candidate toward the clinic, and thrilled to welcome Jared to the Kymera team to support our move to become a fully integrated biotech company,” said Laurent Audoly, PhD, CEO, Kymera Therapeutics. “Jared brings invaluable experience in drug development and leveraging novel discovery platforms to successfully launch new therapies for patients. He also has incredible depth of knowledge in translational immunology and tumor biology – key areas of focus for the company.”
Kymera Therapeutics has developed a pioneering targeted protein degradation platform designed to move beyond empirical approaches to drug discovery to rationally design protein degrading therapies for diseases that have not been adequately addressed. The company is actively pursuing drug candidates to treat cancer, autoimmune and inflammatory diseases.
“It’s exciting to find myself once again at a new frontier in drug discovery,” said Dr. Gollob. “I was compelled by the rigor of Kymera’s science, team and plan and the incredible sense of urgency to turn this exciting technology into meaningful therapeutics for patients.”
At Alnylam, Dr. Gollob led early and late stage clinical programs in infectious disease, oncology, and amyloidosis, which resulted in the first proof of concept for RNA interference therapeutics in humans, and culminated in the FDA and EMA approvals of ONPATTROTM for the treatment of hereditary transthyretin amyloidosis. Prior to joining Alnylam, Dr. Gollob held academic positions at Harvard Medical School and Duke University School of Medicine, and was on staff at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Duke University Medical Center, where he was engaged in both clinical and laboratory research in oncology and immunology. Dr. Gollob has authored more than 50 peer-reviewed papers published in top-tier medical and scientific journals. He received his BA and MD from Columbia University, and completed clinical training in internal medicine and medical oncology at Massachusetts General Hospital and the Dana-Farber Cancer Institute, respectively.
Dr. Gollob assumes responsibility for advancing clinical candidates identified by Kymera’s proprietary Pegasus™ targeted protein degradation platform, working closely with our scientists and overseeing clinical strategy and line of sight to registration for the organization.
# # #
About Kymera Therapeutics
Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Powered by Pegasus™, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients.
Pegasus™ is Kymera Therapeutic’s proprietary protein degradation platform, created by its team of experienced drug hunters to improve the effectiveness of targeted protein degradation and generate a pipeline of novel therapeutics for previously undruggable diseases. The platform consists of informatics driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities and degradation tools.